Related Experiment Video
Updated: May 31, 2026

Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
Memantine prevents aluminum-induced cognitive deficit in rats
Raafat A Abdel-Aal1, Abdel-Azim A Assi, Botros B Kostandy
1Department of Pharmacology, Faculty of Medicine, University of Assiut, Egypt. raafat abdelbadea@yahoo.com
Abstract:
Memantine, a noncompetitive NMDA receptor blocker, has been demonstrated to be neuroprotective against various neurotoxins. Aluminum, a well-known neurotoxin, has been suggested to be a contributing factor in Alzheimer's disease. In this study we investigated the possible effect of memantine on aluminum-induced cognitive impairment in rats. Rats were exposed to aluminum chloride (100mg/kg/day) and memantine (5, 10 and 20mg/kg/day) for 60 days. Cognitive functions were evaluated using three tests: Morris water maze, radial arm maze and passive avoidance tests. Results showed that memantine failed at low doses to have any significant influence on aluminum-induced memory deficit, but the 20mg/kg dose was found to cause significant enhancement of memory in the aluminum-exposed rats. This is the first study to demonstrate the protective role of memantine against aluminum-induced neuronal dysfunction. Biochemical and histological investigations are highly indicated to clarify the possible pharmacodynamic basis.
More Related Videos
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Treatment
Long-term Depression
Calcium Ion Concentration Mechanism
If over time, all...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...